Skip to main content
Erschienen in: World Journal of Urology 6/2020

10.09.2019 | Original Article

How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies

verfasst von: Ángel Borque-Fernando, Luis Mariano Esteban, Ana Celma, Sarai Roche, Jacques Planas, Lucas Regis, Inés de Torres, Maria Eugenia Semidey, Enrique Trilla, Juan Morote

Erschienen in: World Journal of Urology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To combine multiparametric MRI (mpMRI) findings and clinical parameters to provide nomograms for diagnosing different scenarios of aggressiveness of prostate cancer (PCa).

Methods

A cohort of 346 patients with suspicion of PCa because of abnormal finding in digital rectal examination (DRE) and/or high prostate specific antigen (PSA) level received mpMRI prior to prostate biopsy (PBx). A conventional 12-core transrectal PBx with two extra cores from suspicious areas in mpMRI was performed by cognitive fusion. Multivariate logistic regression analysis was performed combining age, PSA density (PSAD), DRE, number of previous PBx, and mpMRI findings to predict three different scenarios: PCa, significant PCa (ISUP-group ≥ 2), or aggressive PCa (ISUP-group ≥ 3). We validate models by ROC curves, calibration plots, probability density functions (PDF), and clinical utility curves (CUC). Cut-off probabilities were estimated for helping decision-making in clinical practice.

Results

Our cohort showed 39.6% incidence of PCa, 32.6% of significant PCa, and 23.4% of aggressive PCa. The AUC of predictive models were 0.856, 0.883, and 0.911, respectively. The PDF and CUC showed 11% missed diagnoses of significant PCa (35 cases of 326 significant PCa expected in 1000 proposed Bx) when choosing < 18% as the cutoff of probability for not performing PBx; the percentage of saved PBx was 47% (474 avoided PBx in 1000 proposed).

Conclusion

We developed clinical and mpMRI-based nomograms with a high discrimination ability for three different scenarios of PCa aggressiveness (https://​urostatisticalso​lutions.​shinyapps.​io/​MRIfusionPCPredi​ction/​). Specific clinical cutoff points allow us to save a high number of PBx with a minimum of missed diagnoses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Sanda MG, Cadeddu J, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199:990–997. https://doi.org/10.1016/j.juro.2018.01.002 CrossRefPubMed Sanda MG, Cadeddu J, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199:990–997. https://​doi.​org/​10.​1016/​j.​juro.​2018.​01.​002 CrossRefPubMed
6.
Zurück zum Zitat Carroll PR, Parsons JK, Andriole G, Bahnson RR, Carlsson S, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Jarrard D, Kibel AS, Kim S, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Wake R, Yuh B (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Prostate Cancer Early Detection Version 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed 14 May 2019 Carroll PR, Parsons JK, Andriole G, Bahnson RR, Carlsson S, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Jarrard D, Kibel AS, Kim S, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Wake R, Yuh B (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Prostate Cancer Early Detection Version 1.2019. https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​prostate_​detection.​pdf. Accessed 14 May 2019
7.
Zurück zum Zitat Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington T, Ellis R, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel ME, Lang JM, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach III M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Prostate Cancer Version 1.2019. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 14 May 2019 Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington T, Ellis R, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel ME, Lang JM, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach III M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J (2019) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Prostate Cancer Version 1.2019. https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​prostate.​pdf. Accessed 14 May 2019
8.
Zurück zum Zitat Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, Gillesen S, Grummel J, Henry AM, Lam TB, Mason MD, van der Kwast T, van der Poel HG, Rouvière O, Tilki D, Wiegel T, van der B T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2019) EAU-EANM-ESTRO-ESUR-SIOG, guidelines on prostate cancer. 2019. https://uroweb.org/guideline/prostate-cancer/#3. Accessed 14 May 2019 Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, Gillesen S, Grummel J, Henry AM, Lam TB, Mason MD, van der Kwast T, van der Poel HG, Rouvière O, Tilki D, Wiegel T, van der B T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moris L, Schoots IG, Willemse PM (2019) EAU-EANM-ESTRO-ESUR-SIOG, guidelines on prostate cancer. 2019. https://​uroweb.​org/​guideline/​prostate-cancer/​#3. Accessed 14 May 2019
12.
14.
Zurück zum Zitat Rubio-Briones J, Borque A, Esteban LM, Casanova J, Fernandez-Serra A, Rubio L, Casanova-Salas I, Sanz G, Domínguez-Escrig J, Collado A, Gómez-Ferrer A, Iborra I, Ramírez-Backhaus M, Martínez F, Calatrava A, Lopez-Guerrero JA (2015) Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. BMC Cancer 15:633. https://doi.org/10.1186/s12885-015-1623-0 CrossRefPubMedPubMedCentral Rubio-Briones J, Borque A, Esteban LM, Casanova J, Fernandez-Serra A, Rubio L, Casanova-Salas I, Sanz G, Domínguez-Escrig J, Collado A, Gómez-Ferrer A, Iborra I, Ramírez-Backhaus M, Martínez F, Calatrava A, Lopez-Guerrero JA (2015) Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. BMC Cancer 15:633. https://​doi.​org/​10.​1186/​s12885-015-1623-0 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Borque-Fernando A, Esteban-Escaño LM, Rubio-Briones J, García-Ruiz R, Tejero-Sánchez A, Muñoz-Rivero MT, Alfaro-Torres J, Marquina-Ibáñez IM, Hakim-Alonso S, Mejía-Urbáez E, Gil-Fabra J, Gil-Martínez P, Álvarez-Alegret R, Sanz G, Gil-Sanz MJ (2017) A preliminary study of the ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for predicting high-grade prostate cancer. Actas Urol Esp 40:155–163CrossRef Borque-Fernando A, Esteban-Escaño LM, Rubio-Briones J, García-Ruiz R, Tejero-Sánchez A, Muñoz-Rivero MT, Alfaro-Torres J, Marquina-Ibáñez IM, Hakim-Alonso S, Mejía-Urbáez E, Gil-Fabra J, Gil-Martínez P, Álvarez-Alegret R, Sanz G, Gil-Sanz MJ (2017) A preliminary study of the ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for predicting high-grade prostate cancer. Actas Urol Esp 40:155–163CrossRef
16.
Zurück zum Zitat Borque A, Rubio-Briones J, Esteban LM, Sanz G, Domínguez-Escrig J, Ramírez-Backhaus M, Calatrava A, Solsona E (2014) Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer. BJU Int 113:878–886. https://doi.org/10.1111/bju.12532 CrossRefPubMed Borque A, Rubio-Briones J, Esteban LM, Sanz G, Domínguez-Escrig J, Ramírez-Backhaus M, Calatrava A, Solsona E (2014) Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer. BJU Int 113:878–886. https://​doi.​org/​10.​1111/​bju.​12532 CrossRefPubMed
18.
Zurück zum Zitat van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD (2017) A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int 120:774–781. https://doi.org/10.1111/bju.13814 CrossRefPubMed van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD (2017) A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int 120:774–781. https://​doi.​org/​10.​1111/​bju.​13814 CrossRefPubMed
19.
Zurück zum Zitat Radtke JP, Bonekamp D, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Hadaschik BA, Wiesenfarth M, Stock C (2017) Combined clinical parameters and multiparametric MRI for advanced risk modeling of prostate cancer—patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol 72:888–896. https://doi.org/10.1016/S1569-9056(17)30557-2 CrossRefPubMed Radtke JP, Bonekamp D, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Hadaschik BA, Wiesenfarth M, Stock C (2017) Combined clinical parameters and multiparametric MRI for advanced risk modeling of prostate cancer—patient-tailored risk stratification can reduce unnecessary biopsies. Eur Urol 72:888–896. https://​doi.​org/​10.​1016/​S1569-9056(17)30557-2 CrossRefPubMed
21.
Zurück zum Zitat Alberts AR, Roobol MJ, Verbeek FJM, Schoots IG, Chiu PK, Osses F, Tijsterman JD, Beerlage HP, Mannaerts CK, Albers P, Arsov C, Schimmo L, Novara G, Vickers A (2019) Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the rotterdam european randomized study of screening for prostate cancer risk calculators. Eur Urol 75:310–318. https://doi.org/10.1016/j.eururo.2018.07.031 CrossRefPubMed Alberts AR, Roobol MJ, Verbeek FJM, Schoots IG, Chiu PK, Osses F, Tijsterman JD, Beerlage HP, Mannaerts CK, Albers P, Arsov C, Schimmo L, Novara G, Vickers A (2019) Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the rotterdam european randomized study of screening for prostate cancer risk calculators. Eur Urol 75:310–318. https://​doi.​org/​10.​1016/​j.​eururo.​2018.​07.​031 CrossRefPubMed
26.
28.
Zurück zum Zitat Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM (2015) A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 68:464–470. https://doi.org/10.1016/j.eururo.2014.10.021 CrossRefPubMed Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM (2015) A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol 68:464–470. https://​doi.​org/​10.​1016/​j.​eururo.​2014.​10.​021 CrossRefPubMed
Metadaten
Titel
How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies
verfasst von
Ángel Borque-Fernando
Luis Mariano Esteban
Ana Celma
Sarai Roche
Jacques Planas
Lucas Regis
Inés de Torres
Maria Eugenia Semidey
Enrique Trilla
Juan Morote
Publikationsdatum
10.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 6/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02946-w

Weitere Artikel der Ausgabe 6/2020

World Journal of Urology 6/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.